REGENERON PHARMACEUTICALS, INC. (REGN)
About REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $14.3B
- Net income
- $4.5B
- Total assets
- $40.6B
- Market cap
- $68.8B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $68.8B
- Dividend yield
- 0.46%
- Shares outstanding
- 84.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 2, 1991
Regeneron Pharmaceuticals, Inc. (REGN) Stock Price
- Profitable — net income of $4.5B in FY2025.
- Trading 4% below its 52-week high.
- Pays a dividend yielding about 0.46% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review REGENERON PHARMACEUTICALS, INC..
Write a review
News about REGENERON PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
Regeneron Pharmaceuticals, Inc.: frequently asked questions
Is Regeneron Pharmaceuticals, Inc. an American company?
Yes — Regeneron Pharmaceuticals, Inc. is an American company. Regeneron Pharmaceuticals, Inc. is incorporated in New York, United States and headquartered in Tarrytown, New York. Its legal-entity record reports no foreign parent — the company is independently American-owned.
Where is Regeneron Pharmaceuticals, Inc. incorporated?
Regeneron Pharmaceuticals, Inc. is legally incorporated in New York, United States, according to its GLEIF legal-entity record.
Who owns Regeneron Pharmaceuticals, Inc.?
Regeneron Pharmaceuticals, Inc. reports no parent company in its legal-entity record — it is independently owned rather than a subsidiary.
Is Regeneron Pharmaceuticals, Inc. traded on a US stock exchange?
Yes — Regeneron Pharmaceuticals, Inc. trades under the ticker REGN on the NASDAQ.
Where is Regeneron Pharmaceuticals, Inc. headquartered?
Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, New York, United States.
Is Regeneron Pharmaceuticals, Inc. publicly traded?
Yes — Regeneron Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol REGN on the NASDAQ.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
